Ipamorelin
A selective ghrelin-receptor agonist studied in growth-hormone release research.
From$46.00Select size
CJC-1295 + Ipamorelin Blend
A combined GHRH analog and ghrelin-receptor agonist preparation used in secretagogue research.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 2
- Availability
- In stock
Select size
Quantity
1
Total
$79.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Certificate for this lot is pending. Every batch we ship is published at /coa before it goes out.
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
A co-formulation of two compounds that act on different receptors: CJC-1295, a GHRH-receptor analog developed by ConjuChem, and ipamorelin, a selective growth-hormone secretagogue described by Novo Nordisk researchers in 1998. The pairing is a supplier formulation; the combination itself has no independent discovery history or characterisation.
What has been characterised
The interest in pairing these two is mechanistic rather than empirical: they engage two separate receptor systems on the somatotroph — the GHRH receptor and the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a). Each is characterised independently in the literature cited under its own entry. No peer-reviewed work characterises this specific blend as a single entity. Neither constituent is FDA-approved for human use, and both classes appear on the WADA Prohibited List.
Sources
- 1.“Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol, 1998. PMID 9849822
- 2.“Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” Endocrinology, 2005. PMID 15817669
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
HCG
A glycoprotein gonadotropin studied in receptor-binding and endocrine-signalling research models.
From$42.00Notify me
Sermorelin
A GHRH(1-29) analog examined in endocrine and pituitary-signalling research.
From$49.00Notify me
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.